MetaCap

Evaxion A/S (EVAX) vs LeonaBio (LONA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

LeonaBio (LONA) has outperformed Evaxion A/S (EVAX) over the past year, losing 56.1% versus a loss of 56.6%. Over five years, LONA leads with a -98.6% price change compared with -99.1% for EVAX. LeonaBio is the larger company by market cap ($26.4 million vs $20.8 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EVAX-56.56%LONA-56.13%
+164%+46%-72%
Nov 21, 20251 yearNov 20, 2026
EVAX-99.19%LONA-98.61%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EVAX versus LONA key metrics
MetricEVAXLONA
Share price$2.25$2.02
Market cap$20.75M$26.41M
1-day change+10.84%-17.89%
YTD return-52.83%-73.32%
1-year return-56.56%-56.13%
5-year return-99.07%-98.55%
EPS (TTM)$-1.00$-22.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.53M—
Revenue growth (YoY)+125.12%—
Net income (latest FY)$-7.71M$-105.61M
Operating margin-122.66%—
Net margin-102.38%—
52-week high$6.92$14.21
52-week low$2.03$1.91
Distance from 52-week high-67.49%-85.78%
Analyst consensusnonenone
Avg. price target upside+400.00%+757.92%
Average volume85.00K195.37K
Shares outstanding9.22M13.08M
Employees4619
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Evaxion A/S

EVAX stock →

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees

About LeonaBio

LONA stock →

LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees

EVAX vs LONA FAQ

Which is bigger, Evaxion A/S or LeonaBio?

LeonaBio (LONA) is larger, with a market capitalization of $26.41M compared with $20.75M for Evaxion A/S (EVAX).

Which stock has performed better over the past year, EVAX or LONA?

LONA returned -56.13% over the past 12 months, compared with -56.56% for EVAX (price return, excluding dividends). Past performance does not predict future results.

Are Evaxion A/S and LeonaBio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons